Design and structure of peptide and peptidomimetic antagonists of protein-protein interaction

Current Protein and Peptide Science

Volumn 6, Issue 2, 2005, Pages 151-169

  Sillerud, Laurel O ^a   Larson, Richard S ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; ARGINYLGLYCYLASPARTIC ACID; ARGINYLGLYCYLASPARTYLSERYLCYSTEINYLARGINYLGLYCYLASPARTYLSERYLTYROSINE; ASPARTIC ACID; BENZOIC ACID DERIVATIVE; CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; CONTRAST MEDIUM; CYSTEINYLTRYPTOPHYLLEUCYLASPARTYLVALYLCYSTEINE; FRADAFIBAN; GANTOFIBAN; INTEGRIN; ISOLEUCINE; LEUCYLASPARTYLVALINE; LIGAND; MONOCLONAL ANTIBODY LM 609; PEPTIDE CS 1; PEPTIDE DERIVATIVE; PEPTIDOMIMETIC ANTAGONIST; POLYPEPTIDE; PROLINE; PROTEIN INHIBITOR; RADIOISOTOPE; RECEPTOR BLOCKING AGENT; SB 223245; SC 65811; SC 69000; SCH 221153; SH 306; SIBRAFIBAN; TECHNETIUM 99M; THREONYLGLUTAMINYLISOLEUCYLSERYLPROLINE; TIROFIBAN; TRYPTOPHAN; TYROSINE; UNCLASSIFIED DRUG; XEMILOFIBAN;

AMINO ACID SEQUENCE; CELL ADHESION; DRUG DESIGN; DRUG STRUCTURE; DRUG TARGETING; MELANOMA; NONHUMAN; PROTEIN DOMAIN; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

AMINO ACIDS; BINDING SITES; DRUG DESIGN; HUMANS; INTEGRINS; LIGANDS; MOLECULAR CONFORMATION; MOLECULAR MIMICRY; PEPTIDES; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING;

EID: 18144394737     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/1389203053545462     Document Type: Review

References (96)

1. Carlson, H.A. (2002) Protein flexibility and drug design: how to hit a moving target. Curr. Opin. Chem. Biol. 6, 447-452.
2. http://merops.saiiger.ac.uk/
3. Mathews, C. K., van Holde, K. E. and Ahern, K. G. (2000) Bio-chemistry (3rd Edition) Benjamin/Cummings, San Francisco, p. 128.
4. Lo Conte, L., Chothia, C. and Janin, J. (1999) The atomic structure of protein-protein recognition sites. J. Mol. Biol. 285, 2177-2198.
5. Jones, S. and Thornton, J. M. (1996) Principles of Protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A., 93, 13-20.
6. Clackson, T., Ultsch, M. H., Wells, J. A. and de Vos, A. M. (1998) Structural and functional analysis of the 1:1 growth hormone: receptor complex reveals the molecular basis for receptor affinity. J. Mol. Biol., 277, 1111-1128.
7. Bogan, A. A. and Thorn, K.S. (1998) Anatomy of hot spots in protein interfaces. J. Mol. Biol., 280, 1-9.
8. Marshall, G. R. (1992) Three-dimensional structure of peptide-protein complexes: Implications for recognition. Curr. Opin. Struct. Biol., 2, 904-919.
9. Oprea, T. I. (2002) Current trends in lead discovery: are we looking for the appropriate properties? J. Comput. Aided Mol. Des., 16, 325-34.
10. Larson, R. S. and Springer, T. A. (1990) Structure and function of leukocyte integrins. immunol. Rev., 114, 181-217.
11. Hynes RO. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell, 69, 11-25.
12. Hynes, R. O. (2002) Integrins: bidirectional, allosteric signaling machines. Cell, 110, 673-87.
13. Shimaoka, M. and Springer, T. A. (2003) Therapeutic antagonists and conformational regulation of integrin function. Nat. Rev. Drug Discov. 2, 703-16.
14. Pierschbacher, M. D., Hayman, E. G., and Ruosiahti, E. ( 1983) Synthetic peptide with cell attachment activity of fibronectin. Proc. Natl. Acad. Sci. U. S. A., 80, 1224-1227.
15. Pierschbacher, M. D., and Ruoslahti, E. (1984) Cell attachment activity of fibronectin can be duplicated by small synthetic fragments of the molecule. Nature, 309, 30-33.
16. Mould, A. P., Komoriya, A., Yamada, K.M. and Humphries, M. J. (1991) The CS5 peptide is a second site in the IIICS region of fibronectin recognized by the integrin alpha 4 beta 1. Inhibition of alpha 4 beta 1 function by RGD peptide homologues. J. Biol. Chem. 266, 3579-3585.
17. Wayner, E. A. and Kovach, N. L. (1992) Activation-dependent recognition by hematopoietic cells of the LDV sequence in the V region of fibronectin. J. Cell. Biol., 116, 4898-4897.
18. Bochner, B.S., Luscinskas, F.W., Gimbrone, M.A. Jr., Newman, W., Sterbinsky, S.A., Derse-Anthony, C.P., Klunk, D. and Schleimer, R.P. (1991) Adhesion of human basophils, eosinophils, and neutrophils to interleukin I-activated human vascular endothelial cells: contributions of endothelial cell adhesion molecules. J. Exp. Med., 1173, 1553-1557.
19. Clements, J. M., Newham, P., Shepherd, M., Gilbert, R., Dudgeon, T. J., Needham, L. A., Edwards, R. M., Berry, L., Brass, A., and Humphries, M. J. (1994) Identification of a key integrin-binding sequence in VCAM-1 homologous tot he LDV active site in fibronectin. J. Cell Sci., 107, 2127-2135.
20. Wang, J., Pepinsky, R.B., Stehle, T., Liu, J., Karpusas, M., Browning, B., and Osborn, L. (1995) The Crystal Structure of an N-Terminal Two-Domain Fragment of Vascular Cell Adhesion Molecule 1 (VCAM-1): A Cyclic Peptide Based on the Domain 1 C-D Loop can Inhibit VCAM-1- {alpha}4 lntegrin Interaction. Proc. Natl. Acad Sci. U.S.A. 92, 5714-5718.
21. Mian IS, Bradwell AR, Olson AJ. Structure, function, and properties of antibody combining sites. J. Mol. Biol. 217(1991)133-151.
22. Lin, K., Ateeq, H.S., Hsiung, S.H., Chong, L.T., Zimmerman, C.N., Castro, A., Lee, W.C., Hammond, C.E., Kaikunte, S., Chen, L.L., Pepinsky, R.B., Leone, D.R., Sprague, A.G., Abraham, W.M., Gill, A., Lobb, R.R. and Adams, S.P. (1999) Selective, tight-binding inhibitors of integrin alpha4beta1 that inhibit allergic airway responses. J. Med. Chem., 42, 920-934.
23. Chen, X., Park, R., Shahinian, A.H., Bading, J.R. and Conti, P.S. (2003) Syntheses of second generation, 14-membered ring betaturn mimics. Chem. Commun. (Camb)., 21, 1674-1675.
24. Lee, H.B., Pattarawarapan, M., Roy, S. and Burgess, K. ( 2003) Nonpeptide RGD antagonists: a novel class of mimetics, the 5,8-disubstituted 1-azabicyclo[5.2.0]non-2-one lactam. Bioorg. Med. Chem. Lett. 13, 1561-1564.
25. Bourguet, E., Baneres, J.L., Parello, J., Lusinchi, X., Girard, J.P. and Vidal, J.P. (2002) Structural analysis of fertilin (beta) cyclic peptide mimics that are ligands for alpha6beta1 integrin. J. Pept. Res. 59, 45-54.
26. Makarem, R., Newham, P., Askari, J.A., Green, L.J., Clements, J., Edwards, M., Humphries, M.J. and Mould, A.P. (1994). Competitive binding of vascular cell adhesion molecule-1 and the HepII/IIICS domain of fibronectin to the integrin alpha 4 beta 1. J. Biol. Chem. 269, 4005-4011.
27. Haworth, D., Rees, A., Alcock, P.J., Wood, L.J., Dutta, A.S., Gormley, J.J., Jones, H.B., Jamieson, A. and Reilly, C.F. (1999) Anti-inflammatory activity of c(ILDV-NH(CH2)5CO), a novel, selective, cyclic peptide inhibitor of VLA-4-mediated cell adhesion. Br. J. Pharmacol. 126, 1751-60.
28. Chou, K. (2000) Prediction of tight turns and their types in proteins. Anal. Biochem., 286, 1-16.
29. Doyle, P.M., Harris, J.C., Moody, C.M., Sadler, P.J., Sims, M., Thornton, J.M., Uppenbrink, J. and Viles, J.H. (1996) Solution structure of a biologically-active cyclic LDV peptide analogue containing a type II″ beta-turn mimetic. Int. J. Pept. Protein-Res., 47, 427-36.
30. Viles, J.H., Mitchell, J.B., Gough, S.L., Doyle, P.M., Harris, C.J., Sadler, P.J. and Thornton, J.M. (1996) Multiple solution conformations of the integrin-binding cyclic pentapeptide cyclo(-Ser-D-Leu-Asp- Val-Pro-). Analysis of the (phi, psi) space available to cyclic pentapeptides. Eur. J. Biochem., 242, 352-62.
31. Vanderslice, P., Ren, K., Revelle, J.K., Kim, D.C., Scott, D., Bjereke, R.J., Yeh, E.T., Beck, P.J. and Kogan, T.P. (1997) A cyclic hexapeptide is a potent antagonist of alpha 4 integrins. J. Immunol. 158, 1710-8.
32. Nowlin, D. M., Gorcsan, F., Moscinski, M., Chiang, S., Lobl, T. J. and Cardarelli, P. M. (1993) A novel cyclic pentapeptide inhibits alpha4beta1 and alpha5beta1 integrin-mediated cell adhesion. J. Biol. Chem. 268, 20352-20359.
33. Jackson, D.Y., Quan, C., Artis, D.R., Rawson, T., Blackburn, B., Struble, M., Fitzgerald, G., Chan, K., Mullins, S., Burnier, J.P., Fairbrother, W.J., Clark, K., Berisini, M., Chui, H., Renz, M., Jones, S. and Fong, S. (1997) Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents. J. Med. Chem., 40, 3359-3368.
34. Humphries, M. J. J. (1990) The molecular basis and specificity of integrin-ligand interactions. Cell Sci., 97, 585-592.
35. Ruoslahti, E. (1991) Integrins. J. Clin. Invest. 87, 1-5.
36. Torshin, I.Y. (2002) Structural criteria of biologically active RGD-sites for analysis of protein cellular function - a bioinformatics study. Med. Sci. Monit. 8, BR301-312.
37. Aota S, Nomizu M, Yamada KM. (1994) The short amino acid sequence Pro-His-Ser-Arg-Asn in human fibronectin enhances cell-adhesive function. J. Biol. Chem. 269, 24756-24761.
38. Pfaff, M., Tangemann, K., Muller, B., Gurrath, M., Muller, G., Kessler, H., Timpl, R. and Engel, J. (1994) Selective recognition of cyclic RGD peptides of NMR defined conformation by alpha IIb beta 3, alpha V beta 3, and alpha 5 beta 1 integrins. J. Biol. Chem., 269, 20233-20238,
39. Cardarelli, P.M., Cobb, R.R., Nowlin, D.M., Scholz, W., Gorcsan, F., Moscinski, M., Yasuhara, M., Chiang, S.L. and Lobi, T.J. ( 1994) Cyclic RGD peptide inhibits alpha 4 beta 1 interaction with connecting segment 1 and vascular cell adhesion molecule. J. Biol. Chem., 269, 18668-18673.
40. Koivunen, E., Gay, D.A. and Ruoslahti, E. (1993) Selection of peptides binding to the alpha 5 beta 1 integrin from phage display library. J. Biol. Chem., 268, 20205-20210.
41. Duggan, M.E., Naylor-Olsen, A.M., Perkins, J.J., Anderson, P.S., Chang, C.T., Cook, J.J., Gould, R.J., Ihle, N.C., Hartmaii, G.D., Lynch, J.J., , Lynch, R.J., Manno, P.D., Schafer, L.W., and Smith, R.L. (1995) Non-peptide fibrinogen receptor antagonists. 7. Design and synthesis of a potent, orally active fibrinogen receptor antagonist. J. Med. Chem., 38, 3332-3341.
42. Koivunen, E., Wang, B. and Ruoslahti, E. (1994) Isolation of a highly specific ligand for the alpha 5 beta 1 integrin from a phase display library. J. Cell. Biol., 124, 373-380.
43. Koivunen, E., Wang, B. and Ruoslahti, E. (1995) Phage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrins. Biotechnology (N. Y.), 13, 265-270.
44. Humphries, J.D., Askari, J.A., Zhang, X.P., Takada, Y., Humphries, M.J. and Mould, A.P. (2000) Molecular basis of ligand recognition by integrin alpha5beta 1. II. Specificity of Arg-Gly-Asp binding is determined by Trp157 of the alpha subunit. J. Biol. Chem. 275, 20337-20345.
45. Pollina, E. (1996) Design and synthesis of RGD mimetics as potent inhibitors of platelet aggregation. J. Undergrad. Sci., 3, 119-126.
46. Dechantsreiter, M.A., Planker, E., Matha, B., Lohof, E., Holzemann, G., Jonczyk, A., Goodman, S.L. and Kessler, H. (1999) N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J. Med. Chem., 42, 3033-3040.
47. Xiong, J.P., Stehle, T., Zhang, R., Joachimiak, A., Frech, M., Goodman, S.L. and Arnaout, M.A. (2002) Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg- Gly-Asp ligand. Science, 296, 151-155.
48. Feuston, B.P., Culberson, J.C., Duggan, M.E., Hartman, G.D., Leu, C.T. and Rodan, S.B. (2002) Binding model for nonpeptide antagonists of alpha(v)beta(3) integrin. J. Med. Chem., 45, 5640-5648.
49. Marinelli, L., Lavecchia, A., Gottschalk, K.E., Novellino, E. and Kessler, H. (2003) Docking studies on alphavbeta3 integrin ligands: pharmaeophore refinement and implications for drug design. J. Med. Chem., 46, 4393-4404.
50. Meinecke, R. and Meyer, B. (2001) Determination of the binding specificity of an integral membrane protein by saturation transfer difference NMR: RGD peptide ligands binding to integrin alphaI-Ibbeta3. J. Med. Chem., 44, 3059-3065.
51. Locardi, E., Mullen, D.G., Mattern, R.H. and Goodman, M. ( 1999) Conformations and pharmacophores of cyclic RGD containing peptides which selectively bind integrin alpha(v)beta3. J. Pept. Sci., 5, 491-506.
52. Mould, A.P., Symonds, E.J., Buckley, P.A., Grossmann, J.G., McEwan, P.A., Barton, S.J., Askari, J.A., Craig, S.E., Bella, J. and Humphries, M.J. (2003) Structure of an integrin-ligand complex deduced from solution x-ray scattering and site-directed mutagenesis. J. Biol. Chem., 278, 39993-39999.
53. 15N-edited 2D transferred nuclear Overhauser effects. J. Am. Chem. Soc., 124, 2862-2863.
54. O'Neil, K.T., Hoess, R.H., Jackson, S.A., Ramachandran, N.S., Mousa, S.A. and DeGrado, W.F. (1992) Identification of novel peptide antagonists for GPIIb/IIIa from a conformationally constrained phage peptide library. Proteins, 14, 509-515.
55. Mousa, S.A., Bozarth, J.M., Naik, U.P. and Slee, A. (2001) Platelet GPIIb/IIIa binding characteristics of small molecule RGD mimetic: distinct binding profile for Roxifiban. Br. J. Pharmacol. 133, 331-336.
56. Keenan, R.M., Miller, W.H., Kwon, C., Ali, F.E., Callahan, J.F., Calvo, R.R., Hwang, S.M., Kopple, K.D., Peishoff, C.E., Samanen, J.M., Wong, A.S., Yuan, C.K. and Huffman, W.F. (1997) Discovery of potent nonpeptide vitronectin receptor (alpha v beta 3) antagonists. J. Med. Chem., 40, 2289-2292.
57. Thorpe, D.S., Yeoman, H., Chan, A.W., Krchnak, V., Lebl, M. and Felder, S. (1999) Combinatorial chemistry reveals a new motif that binds the platelet fibrinogen receptor, gpIIbIIIa. Biochem. Biophys. Res. Commun., 256, 537-541.
58. Koistinen, P. and Heino, J. (2002) Integrins in Cancer Cell Invasion. In: Cell Invasion. (Heino, J. and Kahari, V-M. Eds.) Eurekah.com, Lnades Bioscience, Tx, USA 1-27.
59. Hynes, R.O. (2002) A reevaluation of integrins as regulators of angiogenesis. Nat. Med. 8, 918-921.
60. Legler, D.F., Wiedle, G., Ross, F.P, and Imhof, B.A. (2001) Superactivation of integrin alphavbeta3 by low antagonist concentrations. J. Cell. Sci. 114, 1545-1553.
61. Peter, K., Schwarz, M., Nordt, T. and Bode, C. (2001) Intrinsic activating properties of GP IIb/IIIa blockers. Thromb. Res., 103, Suppl 1:S21-27.
62. Kerr, J.S., Sice, A.M. and Mousa, S.A. (2000) Small molecule alpha(v) integrin antagonists: novel anticancer agents. Expert Opin. Investig. Drugs., 9, 1271-1279.
63. Kerr, J.S., Slee, A.M. and Mousa, S.A. (2002) The alpha v integrin antagonists as novel anticancer agents: an update. Expert Opin. Investig. Drugs. 11, 1765-1774.
64. Jin, H. and Varner, J. (2004) Integrins: roles in cancer development and as treatment targets. Br. J. Cancer. 90, 561-565.
65. Mistry, A., Harbottle, R., Hart, S. and Hodivala-Dilke, K.M. (2003) Integrins and angiogenesis: unlocking the route to gene therapy. Curr. Opin. Mol. Ther., 5, 603-610.
66. Tan, C., Cruet-Hennequart, S., Troussard, A., Fazli, L., Costello,P., Sutton, K., Wheeler, J., Gleave, M., Sanghera, J. and Dedhar, S. (2004) Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 5, 79-90.
67. Sudhakar, A., Sugimoto, H., Yang, C., Lively, J., Zeisberg, M. and Kalluri R. (2003) Human tumstatin and human endostatin exhibit distine antiangiogenic activities mediated by alpha v beta 3 and alpha 5 beta 1 integrins. Proc. Natl. Acad. Sci. U. S. A., 100, 4766-47671.
68. 125 I-labeled RGD peptide are improved by PEGylation. Nucl. Med. Biol. 31, 11-19.
69. Carron, C.P., Meyer, D.M., Pegg, J.A., Engleman, V.W., Nickols, M.A., Settle, S.L., Westlin, W.F., Ruminski, P.G. and Nickols, G.A. (1998) A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res., 58, 1930-1935.
70. Kumar, C.C., Malkowski, M., Yin, Z., Tanghetti, E., Yaremko, B., Nechuta, T., Varner, J., Liu, M., Smith, E.M., Neustadt, B., Presta, M. and Armstrong, L. (2001) Inhibition of angiogenesis and tumor growth by SCH221153, a dual alpha(v)beta3 and alpha(v)beta5 integrin receptor antagonist. Cancer Res., 61, 2232-2238.
71. Haier, J., Goldmann, U., Hotz, B., Runkel, N. and Keilholz, U. (2002) Inhibition of tumor progression and neoangiogenesis using cyclic RGD-peptides in a chemically induced colon carcinoma in rats. Clin. Exp. Metastasis., 19, 665-672.
72. Buerkle, M.A., Pahemik, S.A., Sutter, A., Jonczyk, A., Messmer, K. and Dellian, M. (2002) Inhibition of the alpha-nu integrins with a cyclic RGD peptide impairs angiogenesis, growth and metastasis of solid tumors in vivo. Br. J. Cancer., 86, 788-795.
73. Albelda, S.M., Mette, S.A., Elder, D.E., Stewart, R., Damjanovich, L., Herlyn, M. and Buck, C.A., (1990) Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res., 50, 6757-6764.
74. Seftor, R.E., (1998) Role of the beta3 integrin subunit in human primary melanoma progression: multifunctional activities associated with alpha(v)beta3 integrin expression. Amer. J. Pathol., 153, 1347-1351
75. van Belle, P.A., Elenitsas, R., Satyamoorthy, K., Wolfe, J.T., Guerry, Y., Iv, D., Schuchter, L., van Belle, T.J., Albelda, S., Tahin, P., Herlyn, M. and Elder, D.E. (1999) Progression-related expression of beta3 integrin in melanomas and nevi. Hum. Pathol., 30, 562-5671.
76. Castel, S., Pagan, R., Garcia, R., Casaroli-Marano, R.P., Reina, M., Mitjans, F., Piulats, J. and Vilaro, S. (2000) Alpha v integrin antagonists induce the disassembly of focal contacts in melanoma cells. Eur. J. Cell. Biol., 79, 502-512.
77. Mitjans, F., Meyer, T., Fittschen, C., Goodman, S., Jonczyk, A., Marshall, J.F., Reyes, G. and Piulats, J. (2000) In vivo therapy of malignant melanoma by means of antagonists of alpha v integrins. Int. J. Cancer., 87, 716-23.
78. Brooks, P.C., Montgomery, A.M., Rosenfeld, M., Reisfeld, R.A., Hu, T., Klier, G. and Cheresh, D.A. (1994) Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79, 1157-1164.
79. Buckley, C.D., Pilling, D., Henriquez, N.V., Parsonage, G., Threlfall, K., Scheel-Toellner, D., Simmons, D.L., Akbar, A.N., Lord, J.M. and Salmon, M. (1999) RGD peptides induce apoptosis by direct caspase-3 activation. Nature, 397, 534-539.
80. Adderley, S.R. and Fitzgerald, D.J. (2000) Glycoprotein IIb/IIIa antagonists induce apoptosis in rat cardiomyocytes by caspase-3 activation. J. Biol. Chem., 275, 5760-5766.
81. Sivolapenko, G.B., Skarlos, D., Pectasides, D., Stathopoulou, E., Milonakis, A., Sirmalis, G., Stuttle, A., Courtenay-Luck, N.S., Konstantinides, K. and Epenetos, A.A. (1998) Imaging of metastatic melanoma utilizing a technetium-99m labeled RGD-containing synthetic peptide. Eur. J. Nucl. Med., 25, 1383-1389.
82. Haubner, R., Wester, H.J., Burkhart, F., Senekowitsch-Schmidtke, R., Weber, W., Goodman, S.L., Kessler, H. and Schwaiger, M. (2001) Glycosylated RGD-containing peptides: tracer for tumor targeting and angiogenesis imaging with improved biokinetics. J. Nucl. Med., 42, 326-336.
83. van Hagen, P.M., Breeman, W.A., Bernard, H.F., Schaar, M., Mooij, C.M., Srinivasan, A., Schmidt, M.A., Krenning, E.P. and de Jong, M. (2000) Evaluation of a radiolabelled cyclic DTPA-RGD analogue for tumor imaging and radionuclide therapy.Int. J. Cancer., 90, 186-198.
84. Sipkins, D.A., Cheresh, D.A., Kazemi, M.R., Nevin, L.M., Bednarski, M.D. and Li, K.C. (1998) Detection of tumor angiogenesis in vivo by alphaVbeta3 -targeted magnetic resonance imaging. Nat. Med., 4, 623-626.
85. Winter, P.M., Caruthers, S.D., Kassner, A., Harris, T.D., Chinen, L.K., Allen, J.S., Lacy, EK., Zhang, H., Robertson, J.D., Wickline, S.A. and Lanza, G.M. (2003) Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res., 63, 5838-5843.
86. Shannon, J.P., Silva, M.V., Brown, D.C. and Larson, R.S. ( 2001) Novel cyclic peptide inhibits intercellular adhesion molecule-1-mediated cell aggregation. J. Pept. Res. 58, 140-150.
87. Gottschalk, K.E. and Kessler H. (2002) The structures of integrins and integrin-ligand complexes: implications for drug design and signal transduction. Angew. Chem. Int. Ed. Engl., 41, 3767-3774.
88. Anderson, M.E. and Siahaan, T.J. (2003) Mechanism of binding and internalization of ICAM-1-derived cyclic peptides by LFA-1 on the surface of T cells: a potential method for targeted drug delivery. Pharm. Res., 20, 1523-1532.
89. Shuxing, Z., Ying, W.S., Siahaan, T.J. and Jois, S.D. ( 2003) Solution structure of a peptide derived from the beta subunit of LFA-1. Peptides, 24, 827-835.
90. Anderson, M.E. and Siahaan, T.J. (2003) Targeting ICAM-I/LFA-1 interaction for controlling autoimmune diseases: designing peptide and small molecule inhibitors. Peptides, 24, 487-501.
91. Xu, C.R., Yusuf-Makagiansar, H., Hu, Y., Jois, S.D. and Siahaan, T.J. (2002) Structural and ICAM-1-docking properties of a cyclic peptide from the I-domain of LFA-1: an inhibitor of ICAM-1/LFA- 1-mediated T-cell adhesion. J. Biomol. Struct. Dyn. 19, 789-799.
92. Yusuf-Makagiansar, H., Anderson, M.E., Yakovleva, T.V., Murray, J.S. and Siahaan, T.J. (2002) Inhibition of LFA-1/ICAM-1 and VLA-4/VCAM-1 as a therapeutic approach to inflammation and autoimmune diseases. Med. Res Rev., 22, 146-167.
93. Shimaoka, M., Xiao, T., Liu, J.H., Yang, Y., Dong, Y., Jun, C.D., McCormack, A., Zhang, R., Joachimiak, A., Takagi, J., Wang, J.H. and Springer, T.A. (2003) Structures of the α1 I Domain and its Complex with Icam-1 Reveal a Shape-Shifting Pathway for Integrin Regulation, Cell, 112, 99-111.
94. Sillerud, L.O., Burks, E.J., Wester, M.J., Brown, D.C., Vijayan, S. and Larson, R.S. (2003) NMR-derived model of interconverting conformations of an ICAM-1 inhibitory cyclic nonapeptide. J. Pept. Res., 62, 97-116.
95. Sillerud, L.O., Burks, E.J., Brown, W.M., Brown, D.C., and Larson, R.S. (2004) NMR solution structure of a potent cyclic non-apeptide inhibitor of ICAM-1 mediated adhesion produced by homologous amino acid substitution. J. Pept. Res., 64, 127-140.
96. Koivunen, E., Ranta, T.M., Annila, A., Taube, S., Uppala, A., Jokinen, M., van Willigen, G., Ihanus, E. and Gahmberg, C.G. (2001) Inhibition of beta(2) integrin-mediated leukocyte cell adhesion by leucine-leucine-glycine motif-containing peptides. J. Cell. Biol., 153, 905-916.